ArticleFrontiers in pediatrics2026
Analysis of the interventional effects of ambroxol hydrochloride and ontelukast sodium combined with azithromycin on immune function and C-reactive protein serum expression in children with severe Mycoplasma pneumoniae pneumonia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of the study was to investigate the clinical effects of ambroxol hydrochloride and montelukast sodium combined with azithromycin on immune function, inflammatory cytokines, and pulmonary function in children with severe Mycoplasma pneumoniae pneumonia (SMPP). Methods: A retrospective cohort study was conducted on 103 children with SMPP treated at Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, from February 2023 to February 2025. On the basis of different treatment regimens recorded in the electronic medical record system, the children were divided into a control group ( Results: After treatment, the observation group showed significantly greater improvement in symptoms and signs, immune function, inflammatory cytokines, and pulmonary function compared with the control group (all Conclusion: The triple combination of ambroxol hydrochloride, montelukast sodium, and azithromycin is associated with improved inflammatory status, enhanced immune function, and better pulmonary function in children with SMPP, with a favorable safety profile. These findings warrant confirmation in prospective, multicenter randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.